Core Viewpoint - Huadong Medicine's Biomee®1 and Biomee®2 creams are not yet launched overseas and will be registered as imported cosmetics in China, bypassing the drug approval process and clinical trials [1] Group 1 - The products Biomee®1 and Biomee®2 are currently not available in international markets [1] - The registration process for these products in China will follow the imported cosmetics pathway rather than the drug registration approval route [1] - This approach allows the company to avoid the need for conducting clinical trials domestically [1]

Group 1 - The core viewpoint of the article is that Huadong Medicine has clarified the registration status of its products Biomee®1 and Biomee®2, indicating they are not yet launched overseas and will be registered as imported cosmetics in China rather than through drug approval pathways [2] Group 2 - Biomee®1 and Biomee®2 will not require clinical trials in China, simplifying the registration process for these products [2]